首页> 美国卫生研究院文献>Drugs in RD >A Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis
【2h】

A Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis

机译:Depteptidyl Peptidase-4抑制剂Teneligliptin降低了接受血液透析的慢性肾脏病糖尿病患者血浆富含甘油三酸酯的脂蛋白残留

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

ObjectiveA high plasma level of remnant-like particle cholesterol (RLP-C), which is equivalent to triglyceride-rich lipoprotein remnant, is an important coronary risk marker. RLP-C level is high, independent of other plasma lipids, in patients with chronic kidney disease (CKD) undergoing hemodialysis. The effect of teneligliptin, a dipeptidyl peptidase (DPP)-4 inhibitor, on plasma levels of RLP-C in patients with diabetes mellitus and CKD under hemodialysis was studied.
机译:目的高血浆残留物样颗粒胆固醇(RLP-C)含量相当于富含甘油三酸酯的脂蛋白残留物,是重要的冠心病危险标志物。在患有血液透析的慢性肾脏疾病(CKD)患者中,RLP-C水平较高,与其他血浆脂质无关。研究了二肽基肽酶(DPP)-4抑制剂替奈格列汀对血液透析下糖尿病和CKD患者血浆RLP-C的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号